Heron Therapeutics (HRTX) EBIAT (2016 - 2025)
Historic EBIAT for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$17.5 million.
- Heron Therapeutics' EBIAT fell 26087.05% to -$17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.6 million, marking a year-over-year increase of 5144.99%. This contributed to the annual value of -$13.6 million for FY2024, which is 8771.7% up from last year.
- According to the latest figures from Q3 2025, Heron Therapeutics' EBIAT is -$17.5 million, which was down 26087.05% from -$2.4 million recorded in Q2 2025.
- In the past 5 years, Heron Therapeutics' EBIAT registered a high of $3.7 million during Q4 2024, and its lowest value of -$63.9 million during Q1 2022.
- For the 5-year period, Heron Therapeutics' EBIAT averaged around -$28.6 million, with its median value being -$25.0 million (2023).
- Data for Heron Therapeutics' EBIAT shows a peak YoY increase of 18338.61% (in 2025) and a maximum YoY decrease of 26087.05% (in 2025) over the last 5 years.
- Heron Therapeutics' EBIAT (Quarter) stood at -$54.6 million in 2021, then surged by 63.64% to -$19.9 million in 2022, then soared by 46.03% to -$10.7 million in 2023, then surged by 134.16% to $3.7 million in 2024, then crashed by 577.61% to -$17.5 million in 2025.
- Its last three reported values are -$17.5 million in Q3 2025, -$2.4 million for Q2 2025, and $2.6 million during Q1 2025.